ALK-POSITIVE LARGE B-CELL LYMPHOMA
Clinical trials for ALK-POSITIVE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ALK-POSITIVE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug SGR-1505 enters early human testing for B-Cell cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to find the safest dose and understand side effects. Participants must have measurable disease and be well enough for dail…
Matched conditions: ALK-POSITIVE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New hope for aggressive lymphoma: targeted drug combo under study
Disease control Recruiting nowThis early-phase study tests whether adding the targeted drug polatuzumab vedotin (with or without glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well they tolerate …
Matched conditions: ALK-POSITIVE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 05, 2026 12:05 UTC